Cambridge, UK; 26th February 2021
Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a rare disease specialist pharmaceutical company acquiring, developing and commercializing therapeutics that address unmet patient needs, specializing in gastroenterology, is pleased to support Rare Disease Day 28 February 2021 (https://www.rarediseaseday.org/)
There are around 8,000 rare diseases, affecting an estimated 300 million people worldwide, for whom there are significant unmet clinical needs.
Atlantic Healthcare is focusing on the development of renzapride for the management of gastrointestinal dysmotility in a number of rare disease settings, including systemic scleroderma, cystic fibrosis, and Parkinson’s gastroparesis, for which there are no approved therapies.
In clinical trials involving over 1,000 patients, renzapride has demonstrated efficacy in the management of upper and lower gastrointestinal tract disorders. These trials have shown that it can enhance gastric emptying, reduce small bowel transit time and increase colonic motility.
In clinical studies, renzapride has been found to be safe and well tolerated.
~ ENDS ~
About Atlantic Healthcare
Atlantic Healthcare plc (https://www.atlantichc.com) is a rare disease specialist pharmaceutical company acquiring, developing and commercializing therapeutics that address unmet patient needs, specializing in gastroenterology.
The Company owns the exclusive worldwide rights to alicaforsen, a novel antisense drug, in development for ulcerative colitis and Crohn’s disease. It also owns renzapride, a novel therapy, which has the potential to address the unmet needs of multiple patient groups suffering gastrointestinal motility disorders associated with cystic fibrosis, systemic scleroderma and Parkinson’s disease.
Forward Looking Statements
While Atlantic Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Atlantic Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Atlantic Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.